Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

PURPOSE: Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated improved survival in previously treated patients with advanced non–small-cell lung cancer (NSCLC). CheckMate 012, a phase I, multicohort study, was conducted to explore the s...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Rizvi, Naiyer A., Hellmann, Matthew D., Brahmer, Julie R., Juergens, Rosalyn A., Borghaei, Hossein, Gettinger, Scott, Chow, Laura Q., Gerber, David E., Laurie, Scott A., Goldman, Jonathan W., Shepherd, Frances A., Chen, Allen C., Shen, Yun, Nathan, Faith E., Harbison, Christopher T., Antonia, Scott
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2016
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569693/
https://ncbi.nlm.nih.gov/pubmed/27354481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.66.9861
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料